FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000816
Publisher
BMJ
Online
2020-09-08
DOI
10.1136/jitc-2020-000816
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma
- (2019) Weiyi Peng et al. CLINICAL CANCER RESEARCH
- OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function
- (2019) Fanny Polesso et al. JOURNAL OF IMMUNOLOGY
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
- (2019) Imran G. House et al. CLINICAL CANCER RESEARCH
- Chemokines and cancer: new immune checkpoints for cancer therapy
- (2018) Nathan Karin CURRENT OPINION IN IMMUNOLOGY
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms
- (2018) Xiaolong Zhang et al. Cell Reports
- Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600)
- (2018) Adi Diab et al. CANCER RESEARCH
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies
- (2017) E Casey et al. LEUKEMIA
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)
- (2016) Jeffrey Infante et al. CANCER RESEARCH
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
- (2016) Di Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- OX40 Cooperates with ICOS To Amplify Follicular Th Cell Development and Germinal Center Reactions during Infection
- (2016) Vikas Tahiliani et al. JOURNAL OF IMMUNOLOGY
- OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response
- (2015) Clément Jacquemin et al. IMMUNITY
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
- (2015) Stefanie N. Linch et al. Frontiers in Oncology
- Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
- (2014) Khiyam Hussain et al. BLOOD
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer
- (2012) Alexander Pedroza-Gonzalez et al. HEPATOLOGY
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
- (2010) Michael Croft Annual Review of Immunology
- OX40 induces CCL20 expression in the context of antigen stimulation: An expanding role of co-stimulatory molecules in chemotaxis
- (2010) Wenwei Zhong et al. CYTOKINE
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: An immunohistochemistry-based pilot study
- (2010) Fang Xie et al. PATHOLOGY RESEARCH AND PRACTICE
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- The significance of OX40 and OX40L to T-cell biology and immune disease
- (2009) Michael Croft et al. IMMUNOLOGICAL REVIEWS
- OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas
- (2008) MaryClare Sarff et al. AMERICAN JOURNAL OF SURGERY
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started